Updated on 6 September 2012
The RNAi therapeutics R&D center is composed of two parts, a siRNA drug R&D lab in Silicon Valley, USA, and a pilot R&D base in Nantong, China. It owns an integrated proprietary technical platform of siRNA target screening, RNAi drug structure chemical modification and target tissue delivery.
The life science center focuses on molecular biology product development and provides life science lab services and reagents. This center comprises labs for DNA/RNA purification, PCR amplification, gene cloning, protein expression and purification, cell culture, gene sequencing and bioinformatics. It also has more than 1,000 life science reagents in eight product lines related to molecular biology, cellular biology, proteomics and animal studies, as well as bioservices.
The chemical synthesis center has high volume siRNA synthesis capacity. It owns a full set of technologies of DNA and RNA synthesis, including siRNA synthesis, RNA monomer synthesis, oligo DNA synthesis, DNA and RNA florescence modification, and DNA and RNA phosphate modification.
Biomics has collaborations with several companies in Asia Pacific to provide services. It has collaborated with Benitec, a public Australian RNAi therapeutics research company, with focus on developing anti-HBV siRNA therapeutic. Collaboration with Zetiq, an Israeli company, concentrates on development of a novel cervical cancer diagnostic kit. Biomics is also the sole sponsor of the siRNA-based drug incubator under the National Science & Technology Major Program.
It owns integrated technology platforms, including entire siRNA targets (EsT) library, multiplex siRNA, small ligand RNA (sliRNA) and RNA modification. Together with Genecon Biotech, a subsidiary of the company, it has developed local (transdermal) and systematic delivery system. Now, the company is focusing on second generation delivery systems that can enter hypodermis (epidermis) and follicle (local), and targeted delivery.